Sorrento Therapeutics (SRNE) stock forecast for 2026. Forecast tables and graphs.







Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Sorrento Therapeutics (SRNE) stock forecast for 2026

Updated: June 18, 2024 (11:27)

Sector: Healthcare

The share price of Sorrento Therapeutics, Inc. (SRNE) now

What analysts predict: $
52-week High/Low: $ / $

50/200 Day Moving Average: $ / $

This figure corresponds to the Average Price over the previous 50/200 days. For Sorrento Therapeutics stocks, the 50-day moving average is the support level today.

For Sorrento Therapeutics stocks, the 200-day moving average is the support level today.

Are you interested in Sorrento Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Sorrento Therapeutics stock price in 2026. How much will one Sorrento Therapeutics share be worth in 2026? Is it worth taking profit / loss on SRNE stock now or waiting? What are analysts' forecasts for Sorrento Therapeutics stock?

We forecast Sorrento Therapeutics stock performance using neural networks based on historical data on SRNE stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.

Sorrento Therapeutics, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.

The minimum target price for Sorrento Therapeutics analysts is $. Today 200 Day Moving Average is the support level ( $). 50 Day Moving Average is the support level ( $).




Historical and forecast chart of Sorrento Therapeutics, Inc. stock

The chart below shows the historical price of Sorrento Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the SRNE stock price can be found in the table below.


Sorrento Therapeutics, Inc., a clinical stage Biopharma company, develops treatments for cancer, autoimmune, inflammatory and neurodegenerative diseases. She operates in two segments – Sorrento Therapeutics and Scilex. The company provides cancer therapists through the use of a proprietary r-monoclonal antibody antibody library and targeted delivery conditions that include chimeric antigen receptor T-cell therapy (car-T), dimeric antigen receptor T-cell therapy, and antibody-drug conjugates as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biological substances directly to the lymphatic system. In addition, the company’s clinical programs include anti-CD38 CAR-T therapy for the treatment of multiple myeloma as well as amyloidosis and graft versus host diseases. In addition, he is developing resiniferatoxin, a neopioid-based TRPV1 agonist neurotoxin for the treatment of advanced cancer and osteoarthritis of knee pain; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, the company is developing SEMDEXA, an injectable viscous gel formulation that is a Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system in clinical development for chronic low back pain. She has various collaborations with SmartPharm Therapeutics Inc. to develop a gene-encoded vaccine antibody to protect against COVID-19; Celularity, Inc. to initiate a Phase I / II clinical trial with up to 86 COVID-19 patients; and the Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, and a Research Trials Agreement with the University of Texas Medical Branch at Galveston for preclinical testing of Sorrento’s COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Sorrento Therapeutics (SRNE) Forecast for 2026

Month Target Pes. Opt. Vol., %
Jan 0.01 0.01 0.01 23.95 %
Feb 0.01 0.01 0.01 17.82 %
Mar 0.01 0.01 0.01 16.27 %
Apr 0.01 0.01 0.01 11.71 %
May 0.01 0.01 0.01 18.12 %
Jun 0.01 0.01 0.01 17.56 %
Jul 0.01 0.01 0.01 14.93 %
Aug 0.01 0.01 0.01 18.48 %
Sep 0.01 0.01 0.01 13.61 %
Oct 0.00 0.00 0.00 10.78 %
Nov 0.00 0.00 0.01 15.58 %
Dec 0.00 0.00 0.00 16.17 %

Sorrento Therapeutics information and performance

Sorrento Therapeutics Address

N/A

Market Capitalization: N/A $

Market capitalization of the Sorrento Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of SRNE shares in the company outstanding by the market price of one share.

EBITDA: N/A $

EBITDA of Sorrento Therapeutics is earnings before interest, income tax and depreciation of assets.

PE Ratio: N/A

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: N/A

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: N/A

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: N/A

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: N/A

Enterprise Value (EV) /Revenue

EV To EBITDA: N/A

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: N/A

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Sorrento Therapeutics price target for 2026 by month


Target values for the price of one Sorrento Therapeutics share for Jan 2026.

The weighted average target price per Sorrento Therapeutics share in Jan 2026 is: 0.01.
In Jan, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 23.947% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Feb 2026.

The weighted average target price per Sorrento Therapeutics share in Feb 2026 is: 0.01.
In Feb, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 17.815% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Mar 2026.

The weighted average target price per Sorrento Therapeutics share in Mar 2026 is: 0.01.
In Mar, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 16.266% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Apr 2026.

The weighted average target price per Sorrento Therapeutics share in Apr 2026 is: 0.01.
In Apr, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 11.705% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for May 2026.

The weighted average target price per Sorrento Therapeutics share in May 2026 is: 0.01.
In May, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 18.125% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Jun 2026.

The weighted average target price per Sorrento Therapeutics share in Jun 2026 is: 0.01.
In Jun, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 17.556% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Jul 2026.

The weighted average target price per Sorrento Therapeutics share in Jul 2026 is: 0.01.
In Jul, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 14.933% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Aug 2026.

The weighted average target price per Sorrento Therapeutics share in Aug 2026 is: 0.01.
In Aug, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 18.478% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Sep 2026.

The weighted average target price per Sorrento Therapeutics share in Sep 2026 is: 0.01.
In Sep, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 13.612% volatility is expected.
Pessimistic target level: 0.01
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Oct 2026.

The weighted average target price per Sorrento Therapeutics share in Oct 2026 is: 0.00.
In Oct, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 10.780% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00

Target values for the price of one Sorrento Therapeutics share for Nov 2026.

The weighted average target price per Sorrento Therapeutics share in Nov 2026 is: 0.00.
In Nov, the Positive dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 15.578% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.01

Target values for the price of one Sorrento Therapeutics share for Dec 2026.

The weighted average target price per Sorrento Therapeutics share in Dec 2026 is: 0.00.
In Dec, the Negative dynamics for Sorrento Therapeutics, Inc. shares will prevail with possible monthly volatility of 16.165% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00



Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.